Arjun Kanwal, MD
Cardiovascular Disease · Fairfax, VANPI 1992200521
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,160 of the $11,087 with a category attached, or 73.6%. E.r. Squibb & Sons, L.L.C. accounts for 88.3% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $10,063, more than ten times the $98 reported in 2020.
Across 80 payments — averaging $138.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$10K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$297
- Novartis$253
- AstraZeneca$134
- Astellas Pharma US Inc$99
- Novo Nordisk$88
- plus $428 from 9 others
What the payments were for
- Consulting fees$1,0209%
- Speaking & faculty fees$8,16074%
- Food & beverage$1,80816%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 27 | $9,789 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $297 |
| Novartis | 12 | $253 |
| AstraZeneca | 3 | $134 |
| Astellas Pharma US Inc | 1 | $99 |
| Novo Nordisk | 3 | $88 |
| Amgen | 4 | $78 |
| Merck | 3 | $76 |
| Pfizer | 4 | $68 |
| Esperion Therapeutics, Inc. | 3 | $60 |
| Abiomed | 2 | $46 |
| Lantheus Medical Imaging, Inc. | 1 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| Recor Medical Inc | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $18 |
How this compares
$11,087 in reported general payments places this provider in the 85th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $27,000 |
| Metoprolol Succinate | 19 | $328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $68 | $27,00018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Fairfax
- Eunice YangFairfax$31K
- Abbas EmaminiaFairfax$22K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
- Christopher OconnorFalls Church$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.